Left ventricular hypertrophy is associated with increased sirtuin level in newly diagnosed hypertensive patients

Area of Science:

• Cardiology
• Biochemistry
• Internal Medicine

Background:

• Arterial hypertension is a major global health concern linked to significant mortality and morbidity.
• Sirtuin 1 (SIRT1) plays a protective role in endothelial function, counteracting aging and dysfunction.
• Endothelial dysfunction and aging are implicated in the development of hypertensive complications.

Purpose of the Study:

• To investigate the relationship between serum SIRT1 levels and left ventricular hypertrophy (LVH) in newly diagnosed hypertensive individuals.
• To determine if SIRT1 can serve as a predictive biomarker for LVH in hypertension.

Main Methods:

• A cohort of 125 newly diagnosed hypertensive patients was studied, with comparison to 40 healthy controls.
• Left ventricular hypertrophy (LVH) was diagnosed using transthoracic echocardiography with the cube formula.
• Serum SIRT1 concentrations were quantified using enzyme-linked immunosorbent assay (ELISA).

Main Results:

• Serum SIRT1 levels were significantly elevated in hypertensive patients with LVH compared to those without LVH (14.3 ± 3.9 ng/ml vs. 7.9 ± 3.6 ng/ml, P < 0.001).
• Patients with LVH also showed higher SIRT1 levels compared to healthy controls (14.3 ± 3.9 ng/ml vs. 6.6 ± 2.0 ng/ml, P < 0.001).
• Multivariate analysis confirmed that higher serum SIRT1 independently predicted LVH (OR 1.50; 95% CI, 1.30-1.73; P < 0.001).

Conclusions:

• Serum SIRT1 is a significant independent predictor of left ventricular hypertrophy (LVH) in patients with newly diagnosed hypertension.
• SIRT1 demonstrates potential as a sensitive and specific biomarker for identifying LVH risk in hypertensive individuals.
• These findings highlight SIRT1's role in the pathophysiology of hypertensive heart disease and its clinical utility.